MICRACTIVIH: Exploratory Study on the Role of the Digestive Microbiota in Adults Living With HIV-1
Study Details
Study Description
Brief Summary
Chronic immune activation present in aviremic people living with HIV under treatment promotes the onset of insulin resistance and metabolic syndrome, paving the way for the comorbidities that are currently the main causes of morbidity. This activation continues despite effective antiretroviral therapy. In the ACTIVIH study (NCT02334943) the analysis of 68 AI markers allowed classification of 120 aviremic PLHIV under treatment for at least 2 years according to 5 different immune activation profiles. Among these 5 profiles, Profile 2 was characterized by high blood pressure figures, high waist sizes, low HDL-cholesterol levels, high triglyceridemia, and especially hyperinsulinemia. Several studies have shown that the digestive microbiota of this population is less rich and less diverse than that of healthy subjects. However, the digestive microbiota and in particular bacterial proteins and metabolites seem to play a key role in immune activation in people living with HIV. Finally, the digestive microbiota has already been shown to have an impact on insulin sensitivity.
The study investigators hypothesize that a particular digestive microbiota could promote the appearance of Profile 2. This microbiota could be the cause of digestive dysbiosis leading to intestinal inflammation, digestive permeability and bacterial translocation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Profile 2 People living with HIV with immune activation profile 2: inflammatory profile - high level of sTNFRI |
Other: Stool sample collection
50mg stool sample taken for protein extraction
Other: Blood sample collection
Venous blood sample taken for analysis of serum and plasma
|
| Other profiles People living with HIV with immune activation profiles1 + 3-5: T8, NK, T4 and monocyte profiles |
Other: Stool sample collection
50mg stool sample taken for protein extraction
Other: Blood sample collection
Venous blood sample taken for analysis of serum and plasma
|
Outcome Measures
Primary Outcome Measures
- Nature of gut microbiota bacterial proteins in patients with immune activation profile 2 versus all other profiles [Day 0]
Number of bacterial proteins present in stool samples from patients, identified by high-performance liquid chromatography mass spectrometry
- Nature of gut microbiota taxonomy in patients with immune activation profile 2 versus all other profiles [Day 0]
Number of operational taxonomic units present in stool samples from patients, identified by high-performance liquid chromatography mass spectrometry
- Relative quantification of gut microbiota bacterial proteins in patients with immune activation profile 2 versus all other profiles [Day 0]
Percentage of the various bacterial proteins present in stool samples from patients, identified by high-performance liquid chromatography mass spectrometry (%)
- Relative quantification of gut microbiota taxonomy in patients with immune activation profile 2 versus all other profiles [Day 0]
Percentage of the various operational taxonomic units present in stool samples from patients, identified by high-performance liquid chromatography mass spectrometry (%)
Secondary Outcome Measures
- Richness of Firmicutes and Bacteroidetes in patients with immune activation profile 2 versus all other profiles [Day 0]
Rarefaction curves
- Diversity of Firmicutes and Bacteroidetes in patients with immune activation profile 2 versus all other profiles [Day 0]
Shannon index
- beta-diversity of Firmicutes and Bacteroidetes in patients with immune activation profile 2 versus all other profiles [Day 0]
Unifrac
- Level of phyla and minority species in the stool in patients with immune activation profile 2 versus all other profiles [Day 0]
high-performance liquid chromatography mass spectrometry
- Level of CD14S in serum of patients with immune activation profile 2 versus all other profiles [Day 0]
ng/ml by ELISA
- Level of Lipopolysaccharide Binding Protein (LBP) in serum of patients with immune activation profile 2 versus all other profiles [Day 0]
pg/ml by ELISA
- Level of intestinal fatty acid binding protein (I-FABP) in serum of patients with immune activation profile 2 versus all other profiles [Day 0]
ng/ml by ELISA
- Level of bacterial 16S rDNA in plasma of patients with immune activation profile 2 versus all other profiles [Day 0]
Copies/µl
- Transcriptomic analysis of peripheral blood mononuclear cells [Day 0]
RNAseq
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient informed of the implementation of the study, its objectives, its constraints and the patient's rights.
-
Male and Caucasian patient.
-
Patient with HIV-1 infection determined by positive serology or plasma viral load (HIV RNA) measurement.
-
Patient on effective triple antiretroviral therapy, stable for more than 6 months, with a plasma viral load <50 copies / ml for at least 6 months before inclusion (2 measurements).
-
Patient whose immune activation profile has been characterized beforehand (profiles 1, 2, 3, 4 and 5).
-
The patient must have given their free and informed consent and signed the consent form
-
The patient must be a member or beneficiary of a health insurance plan
Exclusion Criteria:
-
Vulnerable person according to article L1121-6 of the CSP.
-
Adult person protected according to article L1121-8 of the CSP.
-
Patient presenting with a non-infectious pathology which may be the cause of an immune abnormality.
-
Patient having undergone treatment with an immunomodulator molecule or chemotherapy within 60 days before inclusion in the research or has an indication planned for the duration of the research.
-
Patient with a chronic digestive pathology or who had been operated on the previous year
-
The subject is participating in a category 1 interventional study, has participated in another interventional study in the last 3 months or is in a period of exclusion determined by a previous study
-
The subject refuses to sign the consent
-
It is impossible to give the subject informed information
-
The patient is under safeguard of justice or state guardianship
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU Gui de Chauliac | Montpellier | France | ||
| 2 | CHU de Nîmes | Nîmes | France |
Sponsors and Collaborators
- Centre Hospitalier Universitaire de Nīmes
Investigators
- Study Director: Jean-Philippe Lavigne, Centre Hospitalier Universitaire de Nīmes
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AOI GCS-MERRI/2019/JPL-01